Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, for the month of October 2023. The filing, dated October 6, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a standalone financial statement.
Material Changes
The filing does not contain comparative financial data or explicit statements regarding material changes versus prior periods. The content is limited to the announcement of the press release.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed within the body of this Form 6-K. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Verify the specific content of the press release dated October 6, 2023 (Exhibit 99.1), as the Form 6-K itself contains no operational or financial data.
- Confirm the impact of the press release announcement on the company's registration statements (Form F-3 No. 333-255089 and Form S-8 Nos. 333-255124 and 333-272515).
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on October 6, 2023.